ImmuPharma (LON:IMM) Stock Price Down 11.9% - What's Next?

Key Points

• ImmuPharma's stock price fell by 11.9% on Friday, trading as low as GBX 10.70 ($0.14) with a total volume of 6.45 million shares traded.
• The company's market capitalization is £58.32 million, with a P/E ratio of -13.03 and a beta of 1.53.
• ImmuPharma reported a negative earnings per share of GBX (0.38) for the last quarter, with analysts forecasting an EPS of -339.00 for the current year.

ImmuPharma plc (LON:IMM - Get Free Report) fell 11.9% on Friday . The company traded as low as GBX 10.70 ($0.14) and last traded at GBX 10.90 ($0.15). 6,454,819 shares changed hands during trading, a decline of 23% from the average session volume of 8,372,450 shares. The stock had previously closed at GBX 12.38 ($0.16).

ImmuPharma Trading Down 6.3%

The stock has a 50-day simple moving average of GBX 8.75 and a two-hundred day simple moving average of GBX 4.62. The firm has a market capitalization of £58.32 million, a P/E ratio of -13.03 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, research analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.